Ixazomib (Ninlaro), the first oral PI All were approved for use in relapsed/refractory multiple myeloma, although daratumumab was also approved for newly diagnosed disease.

For decades, the diagnosis of multiple myeloma required evidence of end-organ damage characterized by myeloma-defining events (MDEs) known as CRAB: C=Hypercalcemia R=Renal insufficiency A=Anemia B ...